explore -WSS

explore

author：entertainment 2025-09-30 08:50:07 - browse：99192

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Overprescribed: High cost isn't America's only drug problem

focus

WSS

Future doctors should be trained to promote social change

Neuroscience’s long legacy of racism

Pancreatic cancer is often deadly, but new discoveries are raising hope

Intermittent fasting comes with a heart risk? Not so fast

Creating egg and sperm cells from stem cells raises ethical issues

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

entertainment

explore

focus

Jerome Adams on the need for new antivirals for Covid

App could help diagnose ear infections more accurately — and at home

Supreme Court strikes down use of affirmative action

Creating egg and sperm cells from stem cells raises ethical issues

Anesthesiologist group: stop taking Ozempic before surgery

Leading voice in opioid treatment defends methadone clinic system

New air purifier tech could be key to improving indoor air quality

Covid silver lining: Unprecedented look at human immune system

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

entertainment

Four alarming medical procedures we’re glad history forgot

Creating egg and sperm cells from stem cells raises ethical issues

Hundreds died while taking an arthritis drug, but nobody alerted patients

Gene editing the human germline: What are the risks?

People with mental disorders often marry others with same

Harvard scientists, with Google, unveil the most detailed brain map ever

hotspot

focus

focus

knowledge